XOMA Royalty completes acquisition of Mural Oncology

XOMA Royalty Corporation (NASDAQ: XOMA) completed its acquisition of Mural Oncology plc (NASDAQ: MURA) on December 5, 2025, through a scheme of arrangement under Irish law.

The acquisition was executed through XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty, which acquired the entire issued and to be issued share capital of Mural. The scheme of arrangement became effective December 5, 2025.

Distribution of cash consideration to Mural shareholders is expected to commence following the effective date, with DTC participant accounts expected to be credited and check distribution expected to be complete as soon as practicable. Under Irish Takeover Rules requirements, all consideration must be distributed by December 19, 2025.

Mural's shares ceased trading on the NASDAQ Global Market at 8:00 pm Eastern Time on December 4, 2025. The company's admission to trading on the exchange was cancelled effective that time.

The acquisition follows Mural's definitive proxy statement dated September 23, 2025, which also served as a scheme circular under Irish law. Lucid Capital Markets served as financial adviser to Mural, while Davy Corporate Finance advised XOMA Royalty.

Legal advisers included Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP for Mural on U.S. and Irish law matters respectively, and Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP for XOMA Royalty and its subsidiary on U.S. and Irish law matters respectively.

You May Also Be Interested In